Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
about
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseasePotential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesBioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposureLung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled TrialCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateRisk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysisImpact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD.Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary diseaseSalmeterol combined with fluticasone propionate improved COPD in patients during stable stage.Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsSteroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers.Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPDAnti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDEffect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.Pathological networking: a new approach to understanding COPD.Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbationsThe role of bronchodilator treatment in the prevention of exacerbations of COPD.Update in chronic obstructive pulmonary disease 2005.A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.The pharmokinetic limitations of antioxidant treatment for COPD.Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls.Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease.Inhaled therapy for stable chronic obstructive pulmonary disease.Update in chronic obstructive pulmonary disease 2006.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.COPD: what is the unmet need?The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD
P2860
Q24197853-634A5267-3B5C-4AD9-A093-59D33E5BF7B2Q24202510-0ED67374-03A6-4C1B-8CA0-C9CF3C257718Q24243564-3F2700D6-0E2E-4F5F-961A-EA77E4D1BAA0Q28083987-BCC03F97-7404-40DF-857D-A0E9E5B37A78Q28391885-E33CEA66-06FD-4151-AB5C-BCB0B6927255Q30355471-7DC41FE7-4CB6-49F2-A73C-A06BAF1FBA2AQ33591899-450050B9-1CB6-4F2B-8628-BBCA4D24504BQ33604883-C4414F25-F3C6-4B7A-B46A-AFF3687371EDQ33613164-0ADB5863-B5A8-4963-B413-847640DFB35BQ33689926-D0B0AEEF-0360-40BF-8E85-EC95987C6C75Q33966009-A5CFD31B-EA2C-42CC-A01F-3D672D4EF9DFQ34036358-34E27550-C5C9-4F6B-8E6B-EBD70ECB56D7Q34065276-4F681FDB-ED8A-4117-A012-490615F0F6ADQ34171117-AAA10798-36DD-429D-BDAF-C77E118284D6Q34415156-7BB48C8C-21A9-4276-B4F3-439C1265C18CQ35042664-1B4ACB3A-71D9-4DFE-9D0A-A33389C2068BQ35088162-3CAAD514-5853-4638-B63F-5498F4F994AFQ35219711-ABC7EF91-FADC-413D-BCFC-C3FB86443BD5Q35492192-9B139BB3-E863-45D8-8288-FD6EAA00AED5Q35531955-0D720A7F-FFEF-4E52-8A61-0142FA4F8B76Q35602749-86D27103-BBBF-49CC-A047-17366D9B70B5Q35855187-A01F75B9-AD1B-48CC-A1E6-1B1D50247266Q35987189-E5148BFB-876A-4893-A16F-9DDF8811D8F1Q36169173-7EB0B7BF-DD48-443A-B74E-9BCCA7F192C0Q36225454-DC297D1B-766D-494A-B4FE-9C345F91E1AAQ36225899-D09F1618-639F-41B6-B2E3-9A115B1A1504Q36283909-9068DF88-4381-4499-A779-4476DF059A61Q36302882-C541C279-6B6C-4AFD-B765-51923FEFB99AQ36389519-6A6572EA-F525-4CAF-8E10-6BBD25AF4A74Q36438669-947DFE84-B5C7-43EB-8673-EE7083D74B58Q36470462-D7D3757D-3AB9-44F9-8226-296FB14BE8BFQ36510045-C94E5306-7D5D-47E9-8779-19018A600D5CQ36514605-2E407861-1740-4127-BCE8-EDCAA462B3E7Q36585746-A443BF65-6D1E-4DB0-A4FB-F62DE9AB50E6Q36687379-43096C6F-23EE-4A08-864C-06A35C531A3CQ36787296-8571384C-A221-46F2-A559-E690ED4333ACQ36838782-64307A8F-BD1A-4C1B-872F-5D907997BBD0Q36956720-7E4040B6-A1F4-4ECA-A95B-60F469D6A9EBQ36964961-8D2B79B6-C61D-41B7-8CA4-9DF68E7E9769Q37017315-84708570-2DF7-4E23-A585-C6FBED428A64
P2860
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@en
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@nl
type
label
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@en
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@nl
prefLabel
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@en
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@nl
P2093
P2860
P1476
Antiinflammatory effects of sa ...... onic obstructive lung disease.
@en
P2093
Debbie Parker
Malcolm Johnson
Neil C Barnes
Peter A Davis
Peter K Jeffery
SCO30005 Study Group
Yu-Sheng Qiu
P2860
P304
P356
10.1164/RCCM.200508-1321OC
P407
P577
2006-01-19T00:00:00Z